PaperPaper Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma External Link Read MorePaper Dual and specific inhibition of NAMPT and PAK4 by KPT-9274 decreases kidney cancer growth External Link Read MorePaper KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells PDF (869.86 KB) Read MorePaper Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies External Link Read MorePaper XPO1, therapeutic … and prognostic target in sarcomas PDF (244.37 KB) Read MorePaper Therapeutic Potential of Targeting PAK Signaling External Link Read MorePaper Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma External Link Read MorePaper The selective inhibitor of nuclear export compound, selinexor, inhibits NF-κb and induces anti-non-small cell lung cancer activity regardless of p53 status PDF (6.11 MB) Read MorePaper First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors External Link Read MorePaper A Method for Quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds PDF (4.05 MB) Read More Previous 1 2 3 4 5 6 7 Next